MedTrace Logo

A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects

NCT06671470 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2024-11-04

No results posted yet for this study

Summary

Primary Objective :

To evaluate the effect of ticagrelor tablets on the pharmacokinetic characteristics of YZJ-1139 in healthy subjects;

Secondary Objective:

To evaluate the safety of ticagrelor tablets in combination with YZJ-1139 tablets in healthy subjects.

Conditions

Interventions

DRUG

YZJ-1139 tablets

Oral dose 20 mg

DRUG

Ticagrelor Tablets

Oral dose 90 mg twice daily

Sponsors & Collaborators

  • Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-22
Primary Completion
2024-09-13
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06671470 on ClinicalTrials.gov